Nurix Therapeutics Stock Discussion

$Nurix Therapeutics (NRIX.US)$ Nurix Therapeutics Presents Data at AACR 2025 Highlighting Transformative Potential of Proprietary DEL-AI Platform Leveraging Machine Learning To Speed Discovery Of Novel Drugs
Benzinga· just
Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company's proprietary DNA encoded library data
Nurix's DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undrug...

$Nurix Therapeutics (NRIX.US)$
Revolutionary Brain-Penetrant Cancer Drugs Outperform Competitors: 10,000 Proteins Destroyed Per Hour

$Nurix Therapeutics (NRIX.US)$
FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight

$Nurix Therapeutics (NRIX.US)$ Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025
GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis
Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing...

$Nurix Therapeutics (NRIX.US)$ Reuters· 5 mins ago
Nurix Announces FDA Clearance of Ind Application for Gs-6791/Nx-0479 - a Novel Irak4 Degrader for Inflammatory Conditions! Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead

$Nurix Therapeutics (NRIX.US)$
Nurix Scores FDA Orphan Drug Win as Q1 Revenue Jumps 11% on Sanofi Deal Success

$Nurix Therapeutics (NRIX.US)$ Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.78) by 14.1 percent. This is a 11.84 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $18.45 million which beat the analyst consensus estimate of $12.71 million by 45.18 percent. This is a 11.26 percent increase over sales of $16.59 million the same peri...

$Nurix Therapeutics (NRIX.US)$
Revolutionary AI Platform Drives 4 Cancer Drug Innovations: Nurix AACR 2025 Spotlight

$Nurix Therapeutics (NRIX.US)$
Breakthrough: Nurix's Novel Brain-Penetrant Cancer Drug Receives Key FDA Designation

$Nurix Therapeutics (NRIX.US)$
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies.
The ODD grants ...